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Abstract
Angiotensin IV is a derivative of the potent vasoconstrictor angiotensin II and it has been shown to
enhance acquisition, consolidation and recall in animal models of learning and memory when
administered centrally or peripherally. Whether changes in angiotensin IV activity underlie the
cognitive effects of those cardiovascular drugs designed to disrupt the peripheral renin-angiotensin
system in humans remains undetermined, but angiotensin IV appears to be a worthy candidate for
consideration in drug development programmes. The mechanism of action of angiotensin IV is still
debated, although its AT4 receptor has been convincingly identified as being insulin-regulated amino
peptidase, which is also known as oxytocinase and placental leucine aminopeptidase. It is speculated
that angiotensin IV may interact with insulin-regulated amino peptidase to enhance neuronal
glucose uptake, prevent metabolism of other neuroactive peptides, induce changes in extracellular
matrix molecules, or induce release of acetylcholine and/or dopamine. All of these things may be
responsible for the beneficial effects on cognition, but none of them are yet proven. Importantly,
strain differences in murine responses to angiotensin IV suggest that some individuals may benefit
from drugs targeted to the AT4 receptor whilst others may be refractory. At present it thus
appears that those individuals with the poorest baseline cognition may receive greatest benefit, but
possible genetic differences in responses to angiotensin IV cannot be ruled-out.
Background
Using object recognition as a model of memory and learn-
ing, we have shown that angiotensin IV causes significant
enhancement in mice. The object recognition test involves
exposing the animals to an open field (60 × 40 cm) in
which are placed two identical ethanol-cleaned porcelain
objects that are novel to the mice, and of sufficient weight
that they cannot be moved or displaced by the subjects.
The mice are allowed 3 minutes to explore the field and
the objects, before being returned to their home cage. One
hour later they are again placed into the same field, with
the same objects, all ethanol-cleaned, and again allowed
3 minutes to explore. At the conclusion of the second
training period the mice are injected subcutaneously with
angiotensin IV and returned to their home cage.
Twenty-four hours later, the animals are returned to the
same field, but now one of the porcelain objects has been
replaced by one of a different shape and colour, but again
ethanol-cleaned. The time spent by the mouse in explor-
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and taking into account general exploratory/locomotor
activity, is taken as a measure of learning and memory
('cognition'). In DBA2 strain mice, saline-treated animals
spent approximately 10% more time exploring the novel
object in comparison to the familiar object. Mice treated
with angiotensin IV, at a dose of 0.47 mg.kg-1 spent
approximately 40% more time exploring the novel object
(p < 0.05) [1].
This was not the first demonstration of an effect of angi-
otensin IV on learning and memory. Braszko et al. [2] had
reported that intracerebroventicular (icv) administration
of 1 nmol of angiotensin IV (0.78 μg) to rats significantly
enhanced recall of a passive avoidance task, and signifi-
cantly enhanced acquisition of an active avoidance task. A
similar study was reported in 2006 by the same group [3]
in which angiotensin IV was given at the same dose and
by the same route to rats 5–15 minutes before recall of a
passive avoidance task and recall of an object recognition
task. The results indicated that angiotensin IV significantly
enhanced recall. Another group of workers (Wright, Hard-
ing and colleagues), reported independently that norleu-
cine-angiotensin IV, a metabolically stable analogue of
angiotensin IV, at 1 nmol icv, enhanced recall of a passive
avoidance task [4] and reversed the amnesic effect of sco-
polamine by enhancing acquisition in a spatial memory
task (Morris water maze) [5].
The work of the groups of Braszko, Harding, and Wright
indicate that angiotensin IV, or its analogue, delivered
directly to the brain, can enhance recall and acquisition in
rats. Our work demonstrates that peripherally adminis-
tered angiotensin IV can enhance memory consolidation
in mice. These disparate findings illustrate the wide-reach-
ing effects of angiotensin IV on learning and memory, and
the possibility of peripheral administration increases its
therapeutic potential.
Angiotensin IV is a component of the renin-angiotensin
system, a metabolic product of the potent vasoconstrictor
angiotensin II (Figures 1 and 2). The significance of this is
that any therapeutic regime aimed at reducing the effects
of angiotensin II on the cardiovascular system may also
alter synthesis of angiotensin IV, with potential knock-on
consequences for cognition. Currently, several therapies
for hypertension and heart failure act via the renin-angi-
otensin system to prevent the vasoconstrictor actions of
angiotensin II. Angiotensin-converting enzyme (ACE)
inhibitors, prevent the conversion of angiotensin I to
angiotensin II by ACE. Antagonists of the angiotensin type
1 (AT1) receptor (angiotensin II antagonists (AIIAs); angi-
otensin receptor blockers) selectively prevent the vasocon-
strictor actions of angiotensin II. More recently, renin
inhibitors, for example, aliskiren, which prevent the syn-
thesis of all of the angiotensins, have been launched. Intu-
itively, with the possible exception of the AT1 receptor
antagonists, all of these therapies might be predicted to
decrease synthesis of angiotensin IV, and thus have detri-
mental effects on learning and memory. That, however,
disregards the fact that alternative enzymatic pathways
exist that may allow the synthesis of the smaller, later
angiotensin peptides despite blockade of enzymes like
ACE [6], and that the brain possesses a complete renin-
angiotensin system that may be affected differently by
therapeutic agents with limited ability to cross the blood
brain barrier than the peripheral renin-angiotensin system
[7]. The evidence in fact indicates that ACE inhibitors, and
AIIAs, when given acutely to cognitively healthy volun-
teers, are able to improve performance on a battery of psy-
chological tests [8,9]. Furthermore, chronic treatment
with these agents has been suggested to have beneficial
effects on cognition in the elderly. A review by Amenta
and colleagues [10] suggests that the treatment of essen-
tial hypertension with ACE inhibitors produces positive
cognitive outcomes that are significantly better than those
induced by either diuretics or beta-blockers, although all
are effective in regulating hypertension. The Study on
Cognition and Prognosis in the Elderly (SCOPE) reported
that treatment of hypertension with the AIIA candesartan
resulted in less cognitive decline than that observed in the
untreated control group [11]. Also looking at another
AIIA, Tedesco and colleagues [12] undertook a 26-month
trial comparing losartan with a diuretic in matched sam-
ples of older (60–73 years) and younger (30–59 years)
mild-to-moderate hypertensives. They reported an abso-
lute improvement in cognition in both groups receiving
losartan, paralleled with reduced systolic and diastolic
Synthetic pathway of the angiotensinsFigure 1
Synthetic pathway of the angiotensins.
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of life scores. Blood pressure and quality of life scores also
improved significantly for the diuretic groups, but there
were no parallel improvements of the cognitive measures.
More recently, Fogari and colleagues reported in three sep-
arate studies that the AIIAs losartan, valsartan, and tem-
isartan produced positive effects on cognition in very
elderly (aged 75–89 years) mild-to-moderate hyperten-
sives, with significant advantages on episodic memory
after 12–24 week treatment programs [13-15]. The mech-
anism underlying the cognitive-enhancing effects of the
ACE inhibitors and the AIIAs is unknown, but there is evi-
dence that manipulation of the renin-angiotensin system
may improve cognitive performance independent of
changes in haemodynamics and protection against vascu-
lar damage. Whether any beneficial effects of ACE inhibi-
tors and AIIAs involve perturbation of angiotensin IV
activity, and whether drugs targeted at angiotensin IV
might have greater therapeutic potential, remains specula-
tion.
The actions of angiotensin IV and its physiological signif-
icance is still an enigma. It is now clear that the brain pos-
sesses a complete renin-angiotensin system and that it is
involved in a range of physiological activities, including
control of fluid balance and blood pressure [16]. More
importantly, the locations of the receptors for the angi-
otensins have now been mapped within the brain. Early
studies concentrated on the areas poorly protected by the
blood brain barrier because of the relative inability of
peripheral angiotensin to cross. Accordingly, AT1 recep-
tors were identified in the circumventricular organs (sub-
forniculate organ, organum vasculosum of the lamina
terminalis, area postrema, median eminence, and anterior
pituitary gland). Since then, more receptors have been
located in areas within the blood brain barrier, including
supraoptic, preoptic, and ventral medial nuclei [6]. Angi-
otensin type 2 (AT2) receptors are found in areas distinct
from AT1 receptors, such as the globus pallidus, inferior
colliculus, locus coeruleus and thalamus [6]. AT4 recep-
tors, which are specific for angiotensin IV, are similarly
widely distributed within the brain and are sometimes in
areas also possessing AT1 or AT2 receptors, for example,
the anterior pituitary, caudate puatamen, globus pallidus,
and thalamus, but also in the hippocampus, which is
devoid of the other angiotensin receptors [6]. It is this
localisation of AT4 receptors to the hippocampus that is
most interesting in terms of angiotensin IV effects on
learning and memory.
The location of the AT4 receptors is well understood, but
the nature of the receptor remains a matter of controversy.
The AT4 receptor was first identified in bovine adrenal
membranes by Harding, Wright, and co-workers [17], and
subsequently in other mammalian tissues, for example,
the brain, kidney, bladder, colon and uterus. It was later
determined to be trimeric and receptors from different
anatomical locations were found to be of equivalent
molecular weights [18]. This suggested that there are no
markedly different subtypes, or that any subtypes were of
a very similar structure. Importantly, it was apparent that
the receptor was not a typical 7-transmembrane domain
G-protein coupled receptor [19]. The landmark finding
came in 2001 when it was discovered that the AT4 receptor
was an insulin-regulated aminopeptidase (IRAP) [20].
The finding was based on sequence homologies of frag-
ments of the human brain AT4 receptor and IRAP, and
similarities of the molecular weights of the two binding
Primary structures of members of the angiotensin family of peptidesFigure 2
Primary structures of members of the angiotensin family of peptides.
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receptor with binding characteristics almost identical to
those of the native AT4 receptor. Albiston has since argued
persuasively that IRAP is the physiological receptor for
angiotensin IV, and that there are several possible mecha-
nisms by which angiotensin IV could be acting to enhance
memory [21]. To summarise the argument: the AT4 recep-
tor and IRAP have identical binding properties for angi-
otensin IV, and expression of the cDNA for IRAP gives rise
to a protein with the binding characteristics of the AT4
receptor. IRAP and its mRNA are co-localised in the brain
with AT4 receptors as determined by radioligand binding.
The endogenous peptide LVV-Hemorphin-7, which is
structurally unrelated to angiotensin IV but known to
bind to AT4 receptors, inhibits the enzymatic activity of
IRAP in vitro, similar to angiotensin IV.
IRAP is a member of a group of enzymes that includes
aminopeptidases A and N, both of which are involved in
the metabolic cascade of the renin-angiotensin system.
Originally identified in adipocytes and skeletal muscle
cells co-localised with the insulin-regulated glucose trans-
porter GLUT4, it is also referred to as oxytocinase or pla-
cental leucine aminopeptidase. In the presence of insulin,
IRAP and GLUT4 translocate to the cell membrane where
GLUT4 mediates glucose uptake. GLUT4 has been identi-
fied in the brain in regions associated with AT4 receptors
and it has been speculated by Albiston that inhibition of
IRAP by angiotensin IV might increase glucose uptake into
brain cells resulting in facilitation of learning and mem-
ory. There is independent evidence that glucose enhances
processes associated with learning and memory [22].
IRAP is also known to hydrolyse angiotensin III, oxytocin,
vasopressin, met-enkephalin, and other endogenous pep-
tides. Some of these peptides, for example, oxytocin and
vasopressin, have been implicated in learning and mem-
ory, and it also has been suggested by Albiston et al. [21],
that inhibition of IRAP by angiotensin IV results in the
accumulation of these peptides that enhance memory.
Wright and Harding [6], however, argue with equalled
cogency that inhibition of IRAP cannot explain the cogni-
tive effects of angiotensin IV. The salient points of their
argument are: the effects of enzyme inhibition and accu-
mulation of endogenous peptides are slow, in the order of
hours or days, whilst the onset of action of angiotensin IV
in some tissues is within seconds; the concentrations of
angiotensin IV required to produce biological, that is, cog-
nitive effects, are well below the concentrations required
to inhibit IRAP; and there is dispute as to whether angi-
otensin IV is a competitive substrate of IRAP or whether it
binds allosterically. If it is a competitive substrate, it
would be difficult to explain the observed effects of the
AT4 receptor antagonist divalinal, which is known to not
only block the effects of angiotensin IV, but also have det-
rimental effects on learning and memory: does divalinal
enhance IRAP activity?
The compromise suggested by Wright and Harding [6] is
that angiotensin IV binds to IRAP, its cognate receptor,
but that there is some other transduction mechanism not
reliant on inhibition of the enzyme. They attempt to inte-
grate the knowledge of the actions of angiotensin IV and
the changes in extracellular matrix molecules associated
with learning and memory, but as yet an unequivocal
mechanism has not been elucidated.
A further suggestion concerning the mechanism of action
of angiotensin IV involves enhancement of long-term
potentiation and acetyl choline release in the hippocam-
pus (see [23] for a review). Braszko [24,25] has produced
evidence that dopamine D1 and D2 receptors are involved
in the cognition-enhancing effects of angiotensin IV.
Whatever the mechanism, it is clear that angiotensin IV
enhances several components of learning and memory,
although this effect does not appear to be consistent for all
individuals.
Our laboratory has previously studied the effects of angi-
otensin II on behaviour, and specifically, the behavioural
effects of the AIIA losartan. In mice, losartan produces
anxiolytic-like and antidepressant-like effects, and, in
some cases, improved learning and memory (see [7] for a
review). Importantly, not all strains of laboratory mouse
exhibit the same behavioural responses to losartan, with
BKW strain mice being particularly sensitive to its anxio-
lytic effects [26]. Furthermore, there is evidence of an
under-active renin-angiotensin system in these mice [26].
Strain differences in the behavioural effects of peripher-
ally administered angiotensin IV were therefore investi-
gated using the object recognition test described above in
an attempt to identify correlations between the behav-
ioural effects of an AIIA and those of angiotensin IV. Fig-
ure 3 illustrates the strain differences in the behavioural
effects of angiotensin IV and shows that DBA2 mice are
more responsive to the effects of angiotensin IV than the
BKW mice identified in the losartan studies [1]. The inter-
esting feature of these results is that the mice with best
inherent cognition benefit least from angiotensin IV. This
either indicates a 'ceiling effect' of the behavioural
method, that is, the inability to measure greater cognition,
or the possibility that angiotensin IV replaces some deficit
responsible for the inherent poor performance.
The remainder of this review will concentrate on the pos-
sible interaction of angiotensin IV, IRAP, also known as
oxytocinase and oxytocin. In rats and mice, low doses of
oxytocin improves social memory, that is, recognition of
conspecific animals [27,28]. That oxytocin is inherentlyPage 4 of 6
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fact that in oxytocin-knockout mice there is a deficit in
social memory that can be restored by icv oxytocin [29].
In normal animals, however, higher doses of oxytocin dis-
rupts social memory [30]. Similarly, high levels in mice
reduce conditioned avoidance [31] and learned helpless-
ness [32]. If angiotensin IV produces its effects via interac-
tion with IRAP and oxytocin, a similar pattern of effects
might therefore be seen. Our experiments studied the
interaction of angiotensin IV both in vitro and on the
behaviour of BKW mice. The results showed that in the
isolated mouse uterus, angiotensin IV induces contrac-
tions, which can only partially be blocked by the AT1
receptor antagonist losartan, indicating some non-AT1
receptor-mediated effect. Furthermore, it potentiated the
contractile effects of oxytocin, suggesting inhibition of
IRAP (oxytocinase) [33]. In the forced swim test, however,
the amnesic effect of oxytocin on learned helplessness was
reduced by angiotensin IV. These results may be inter-
preted as an indication that by inhibiting IRAP (oxytoci-
nase), angiotensin IV increases endogenous oxytocin to
concentrations in the amnesic range, or that angiotensin
IV blocks the behavioural effects of oxytocin by some
other mechanism. Our work, in combination with that of
others, suggests that it is the peptide metabolites of oxy-
tocin that are responsible for the enhanced cognition, and
that angiotensin IV prevents its effects by inhibiting IRAP
(oxytocinase) and the metabolism of oxytocin. The con-
clusion is that oxytocin is unlikely to be involved with the
cognitive actions of angiotensin IV, and that the resistance
of BKW strain mice to the cognitive effects of angiotensin
IV is unlikely to be due to an inherent disorder of oxy-
tocin.
Conclusion
This area of research is still in its infancy. It is known that
angiotensin IV can improve cognition through effects on
acquisition, consolidation, and recall, and that it is possi-
ble to elicit these effects following peripheral administra-
tion of the peptide. Drugs known to interfere with the
renin-angiotensin system have been shown to have bene-
ficial cognitive effects in humans, but whether these
effects involve angiotensin IV is unclear. It is possible,
however, that not all individuals will show similar cogni-
tive responses, as strain differences in mice have been
identified, suggesting either genetic differences in the
effects, replacement of some deficit, or some other ceiling
effect. This may mean that, should an angiotensin IV ana-
logue be developed for the treatment of cognitive deficits,
not all patients would benefit from their use. Importantly,
the mechanism of action of angiotensin IV remains unre-
solved, although inhibition of IRAP, and consequent
increases in endogenous peptides such as oxytocin, cur-
rently seems unlikely.
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